$3.540
+0.167 (+4.73%)終値時点
GALT の同業比較
In the context of the broader market, GALT competes directly with industry leaders such as ZURA and OGCP. With a market capitalization of $357.01M, it holds a significant position in the sector. When comparing efficiency, GALT's gross margin of N/A stands against ZURA's N/A and OGCP's N/A. Such benchmarking helps identify whether Galectin Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Galectin Therapeutics Inc の財務パフォーマンス
Galectin Therapeutics has reported consistent losses, with a net income loss of $9.11 million in Q2 2026, a 21% increase from the previous year. The company's EPS for Q2 2026 is -0.14, reflecting ongoing financial struggles.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
-13.90%
-3.98M
Operating Profit
FY2026Q2
YoY:
+21.17%
-9.11M
Net Income after Tax
FY2026Q2
YoY:
+16.67%
-0.14
EPS - Diluted
FY2026Q2
YoY:
-63.06%
-2.44M
Free Cash Flow
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。